Abstract: Provided herein are, inter alia, antibodies (e.g., humanized antibodies, monoclonal antibodies), antibody fragments (e.g., scFvs) and antibody compositions (e.g., chimeric antigen receptors, bispecific antibodies), which bind human tyrosine kinase-like orphan receptor 2 (ROR2) with high efficiency and specificity. The antibodies and antibody compositions provided herein include novel light and heavy chain domain CDRs and framework regions and are, inter alia, useful for diagnosing and treating cancer and other ROR2-related diseases.

Abstract: The invention provides isolated primate cells preferably human cells that comprise a genetically engineered disruption in a human leukocyte antigen (HLA) class II-related gene, which results in deficiency in MHC class II expression and function. This invention also provides isolated cells further comprising a genetically engineered disruption in a beta-2 microglobulin (B2M) gene, which results in HLA class I/class II deficiency. Also provided are the method of using the cells for transplantation and treating a disease condition.

Abstract: The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind free immunoglobulin light chains (FLC), polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of measuring FLC in a biological sample comprising contacting the sample with the anti-FLC antibody. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-FLC antibody to a subject in need thereof.

Abstract: Provided herein is a consensus molecular subtype (CMS) classifier for colorectal cancer patients. Also provided are methods of using the classifier to identify a clinically beneficial therapeutic regime for each patient as well as methods of treating a patient accordingly Custom Nanostring code sets, which work on formalin-fixed, paraffin-embedded samples, are provide for use in determining the CMS for a colorectal cancer patient.

Abstract: The present invention relates to an anti-LILRB1 antibody having increased specificity for LILRB1, and to uses thereof. Specifically, an anti-LILRB1 antibody or an antigen-binding fragment thereof, and uses thereof in treating cancer are provided.

Abstract: The present invention provides anti-Fzd monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.

Abstract: The disclosure provides methods and compositions, e.g., kits and microarray, for assessing the immune response in a murine tumor model based on the expression of a gene panel that characterizes tumor immune interactions.

Abstract: Disclosed are engineered cells comprising chimeric antigen receptors and uses thereof for treating prostate cancer.

Abstract: Provided is a panel of monoclonal antibodies which specifically bind to CLDN18.2 and do not specifically bind to CLDN18.1, and optionally have an engineered Fc region.

Abstract: The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encelopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).

Abstract: Provided are antibodies specific for the heparan sulfate binding site of Receptor for Advanced Glycation Endproducts (RAGE). Also provided are methods for treating of conditions in which RAGE is involved comprising administration of the antibodies to an individual in need of treatment.

Abstract: Disclosed is a novel CLDN18.2 binding molecule. Also disclosed are a nucleic acid molecule encoding the CLDN18.2 binding molecule, an expression vector and a host cell for expressing the CLDN18.2 binding molecule. Further disclosed are a method for producing the CLDN18.2 binding molecule and use thereof.

Abstract: Disclosed is a LAG-3 binding protein, comprising a light chain variable region and/or a heavy chain variable region. The light chain variable region comprises a CDR1 having an amino acid sequence as shown in SEQ ID NO: 5, a CDR2 having an amino acid sequence as shown in SEQ ID NO: 6, and/or a CDR3 having an amino acid sequence as shown in SEQ ID NO: 7. The heavy chain variable region comprises a CDRI having an amino acid sequence as shown in SEQ ID NO: 8, a CDR2 having an amino acid sequence as shown in SEQ ID NO: 9, and/or a CDR3 having an amino acid sequence as shown in SEQ ID NO: 10. Also disclosed are a bispecific antibody targeting LAG-3 and use thereof. The LAG-3 binding protein and bispecific antibody above can effectively block the binding of LAG-3 to MHC II and activate T cells.

Abstract: Single-domain monoclonal antibodies that specifically bind B7H3 (also known as CD276) are described. The single-domain antibodies include camel VHH and rabbit VH domain nanobodies selected from phage display libraries. Chimeric antigen receptors (CARs) and other antibody conjugates targeted to B7H3 are also described. The single-domain antibodies and conjugates thereof can be used for the diagnosis and treatment of B7H3 expressing solid tumors.

Abstract: Provided herein are proteins that inhibit both the metalloprotease activity and disintegrin activity of human ADAM8, wherein the protein comprises an antigen-binding domain that: (i) binds specifically to human ADAM8; and (ii) binds to an epitope within human ADAM8 that includes at least one amino acid within the sequence of SEQ ID NO: 1, nucleic acids, vectors, compositions, and methods of use thereof (e.g., methods of treatment and methods of diagnosing).

Abstract: The present invention relates to bispecific binding proteins that bind TGF? and PD-L1, and novel anti-PD-L1 antibodies, methods of making the bispecific binding proteins and antibodies, compositions comprising the bispecific binding proteins or antibodies, and methods of using the bispecific binding proteins for blocking TGF?-mediated suppression of T cell activation, for blocking PD-L1-mediated suppression of T cell activation, and for treating cancer.

Abstract: Provided herein are antibodies that bind signal regulatory protein gamma (SIRPy), as well as SIRP? and/or SIRP?1, and methods of using such antibodies (referred to as SIRP antibodies). In some embodiments, the SIRP antibodies are human monoclonal antibodies that bind human SIRPy as well as SIRP? and/or SIRP?1. In some embodiments, the SIRP antibodies provided herein are useful for treating a disease or condition associated with overactivation and/or hyperproliferation of lymphocytes, myeloid cells, or a combination thereof, or a disease or condition associated with SIRP?, SIRP?1 and/or SIRPy activity.

Abstract: Provided herein are, inter alia, Interleukin-1 receptor accessory protein (IL1RAP) antibodies and fragments thereof which may form part of chimeric antigen receptors or bispsecific antibodies and are useful for treating IL1RAP-expressing cancers.

Abstract: Described herein are isolated monovalent antibodies or antibody fragments thereof that bind human properdin. Such antibodies are useful in methods of treatment for diseases mediated by alternative complement pathway dysregulation.

Abstract: The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.